Solène Porte
YOU?
Author Swipe
View article: Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy
Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy Open
Demonstrating cardiovascular (CV) benefits with lipid-lowering therapy (LLT) requires long-term randomized clinical trials (RCTs) with thousands of patients. Innovative approaches such as in silico trials applying a disease computational m…
Mechanistic modeling to understand variability in responses to chronic Hepatitis B treatment Open
Chronic hepatitis B virus (HBV) remains the most common serious liver infection globally, accounting for an estimated 820,000 deaths each year. Patient responses to treatment vary widely, due to complex interplay between viral and immune s…
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme Open
Introduction Inclisiran, an siRNA targeting hepatic PCSK9 mRNA, administered twice-yearly (after initial and 3-month doses), substantially and sustainably reduced LDL-cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inc…
Design of knowledge-based mechanistic model of atherosclerotic cardiovascular disease for in silico trials Open
In silico trials applying a computational model (CM) of atherosclerotic cardiovascular disease (ASCVD) to virtual patients receiving alternative treatments provide an attractive option to complement randomised clinical trials (RCTs) by add…